1 day ago · OSAKA, Japan, Jan 30, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) is pleased to announce that its novel investigational respiratory syncytial virus (RSV) oral antiviral candidate S-337395, which is being jointly developed with UBE Corporation (Head office: Minato-ku, Tokyo; President and Representative ...

Shionogi Announces Positive Results from Phase 2 Human Challenge Trial of Respiratory Syncytial Virus (RSV) Oral Antiviral Candidate S-337395 ⚫ Statistically Significant Reduction in Viral Load Confirmed in Clinical Trial ⚫ Primary Endpoint Achieved ⚫ In the highest dose group, there was an 88.94% reduction in viral load (P<0.0001) ...

1 day ago · In adults aged 60 years and older, the seasonal global incidence of RSV infection is 16.11 cases per 1000 people. 7 RSV can also severely impact the elderly, with an estimated 27.44% developing pneumonia and 24.48% requiring hospitalization 6. About Shionogi in Infectious Disease

1 day ago · Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. The study saw 114 healthy adults inoculated with the virus and ...

S-217622 is made by a company called Shionogi. It is a type of antiviral drug called a protease inhibitor. It stops the virus that causes COVID-19 (SARS-CoV-2) from multiplying. This means there could be fewer viruses for the body to fight, and it may help participants get better faster.

The Shionogi S-217622 Study, which compares an investigational antiviral drug called S-217622, or ensitrelvir, to a placebo to see if it will help adults in the hospital with COVID-19 respiratory infection get better and go home faster.

Feb 15, 2023 · S-217622 suppresses SARS-CoV-2 replication by inhibiting the function of a key virus protein known as 3CL protease. The antiviral reduced COVID-19 symptoms in people with mild-to-moderate COVID-19, regardless of risk factors or vaccination status, according to results shared by Shionogi from a Phase 3 clinical trial conducted mainly in Japan. S ...

Feb 15, 2023 · S-217622 suppresses SARS-CoV-2 replication by inhibiting the function of a key virus protein known as 3CL protease. The antiviral reduced COVID-19 symptoms in people with mild-to-moderate COVID-19, regardless of risk factors or vaccination status, according to results shared by Shionogi from a Phase 3 clinical trial conducted mainly in Japan. S ...

1 day ago · Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese pharmaceutical’s candidate, S-337395, saw success in reducing the impact of the virus as part of a Phase II human challenge study, a type of ...

1 day ago · The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported. ... 2025, press release from Shionogi. 1. S-337395 is being jointly developed by Shionogi and UBE and it functions as an inhibitor of the RSV L protein, a key component in viral replication ...